Transforming Treatment in Multiple Myeloma: The Evolving Role of CAR-T Therapy

This segment explores the treatment journey of a 55-year-old mother and high school teacher with ALK-positive NSCLC and brain metastases, focusing on her experience with lorlatinib therapy.

This segment explores factors influencing patient candidacy for CAR-T therapy, including age, fitness, and relapse specifics, and evaluates key findings from the KarMMa trials to compare ide-cel with other second-line treatment options for multiple myeloma.

This segment highlights clinical experiences with ide-cel in the second-line setting, focusing on observed improvements in efficacy and quality of life, as well as challenges in administration

This segment examines the decision-making process between CAR-T therapy and other innovative treatments, exploring scenarios where alternative therapies may be more appropriate.

This segment discusses the process and critical importance of bridging strategies for patients awaiting CAR T-cell therapy.

This segment highlights the treatment journey of a 68-year-old IT professional with high-risk multiple myeloma, detailing progression after initial D-RVd therapy, refusal of ASCT, and successful transition to cilta-cel CAR-T therapy with manageable adverse events.

This segment examines the evidence supporting cilta-cel in second-line therapy, highlighting key outcomes from the CARTITUDE trials and comparing them to other available second-line treatment options for multiple myeloma.

This segment explores Dr. Rossi's clinical experience with cilta-cel as a second-line therapy, focusing on its efficacy and quality-of-life benefits across diverse patient populations.

This segment examines Dr. Mikhael's approach to comparing ide-cel and cilta-cel for patient selection, emphasizing how patient traits, efficacy, and safety profiles influence treatment decisions across different groups.